ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0126

Prevalence of Dyslipidemia in Fibromyalgia: A Single Center Case Control Study from South India

Mithun CB1, Sandeep Surendran2, Sumanth Madan2, Arun Tiwari3, Spoorthy Raj2, Sekhar Easwar2 and Greeshma Ravindran2, 1Amrita Institute of Medical Sciences, Muvattupuzha, India, 2Amrita Institute of Medical Sciences, Kochi, India, 3Amrita Institute of Medical Sciences, Ernakulam, India

Meeting: ACR Convergence 2021

Keywords: Disease Activity, fibromyalgia, Lipid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Fibromyalgia (FM), a condition characterized by chronic widespread pain, has implications beyond functional disability. FM has been associated with an increased risk of cardiovascular disease in multiple studies, however, there is a paucity of studies looking for dyslipidemia in diagnosed cases of FM. This study sought to explore the association between FM and dyslipidemia.

Methods: This was a case-control study conducted at a tertiary care center in South India from March 2018 to December 2020. FM patients and healthy controls were enrolled in a 1:3 ratio. FM was diagnosed as per the 2016 modified ACR 2010/2011 criteria. Healthy controls who were age, gender, ethnicity and body mass index (BMI) matched were recruited in the study. Fasting lipid profile was obtained from study participants and dyslipidemia was defined by the “Adult treatment panel III criteria”. (1)The revised fibromyalgia impact questionnaire (FIQR) was used as a tool to ascertain disease severity in FM at diagnosis. The prevalence of dyslipidemia in FM was compared with that of healthy controls and odds ratio was calculated. We also studied the correlation of FIQR with fasting lipid profile. Chi- square test and Pearson correlation coefficient was computed and linear regression t test were applied to test statistical significance. A p value < 0.05 was considered significant.

Results: A total of 149 (females- 147) FM cases and 449 healthy controls were enrolled in the study. We noted that dyslipidemia was present in 100 (67%) FM cases and 147 (33%) controls, their difference was statistically significant (p< 0.001; OR 4.193). Subgroup analysis amongst individual age groups showed an increased prevalence of dyslipidemia in the 18-39 years with 17 (57%) amongst FM cases as compared to 18 (15%) in control group (p< 0.001; OR 7.701). In the 40-59 years age group, 73 (68%) FM patients were dyslipidemic as compared to 110 (39%) of the controls (p< 0.001, OR: 3.539). There was no statistically significant difference in prevalence of dyslipidemia between cases and controls of age greater than 60 years. (Figure 1, Figure 2). There was also no statistically significant correlation between FIQR and individual components of lipid profile (p >0.05). (Figure 3)

Conclusion: In this study, dyslipidemia was more prevalent in FM patients as compared to general population. The findings were consistent in subgroup analysis of age groups 18-39 and 40-59 years. However, FM disease severity did not correlate with individual components of fasting lipid profile in our study. These findings emphasize the need for evaluation of dyslipidemia in fibromyalgia patients.

Reference:
1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143–421.

Figure 1.

Figure 2.

Figure 3.


Disclosures: M. CB, None; S. Surendran, None; S. Madan, None; A. Tiwari, None; S. Raj, None; S. Easwar, None; G. Ravindran, None.

To cite this abstract in AMA style:

CB M, Surendran S, Madan S, Tiwari A, Raj S, Easwar S, Ravindran G. Prevalence of Dyslipidemia in Fibromyalgia: A Single Center Case Control Study from South India [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-dyslipidemia-in-fibromyalgia-a-single-center-case-control-study-from-south-india/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-dyslipidemia-in-fibromyalgia-a-single-center-case-control-study-from-south-india/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology